11. 重症筋無力症 Myasthenia gravis Clinical trials / Disease details
臨床試験数 : 332 / 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200057193 | 2022-03-02 | 2022-03-02 | Study on the dominant population of tacrolimus in the treatment of myasthenia gravis | Study on the dominant population of tacrolimus in the treatment of myasthenia gravis | myasthenia gravis | Experimental group:Tacrolimus; | Shijiazhuang People's Hospital | NULL | Pending | 1 | 90 | Both | Experimental group:100; | Phase 4 | China |
| 2 | NCT04768465 (ClinicalTrials.gov) | January 1, 2021 | 21/2/2021 | Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis | Effectiveness and Safety of Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis: A Real-world Study | Myasthenia Gravis | Drug: Pyridostigmine, Prednisone, Tacrolimus;Drug: Pyridostigmine, Tacrolimus | Da, Yuwei, M.D. | NULL | Recruiting | 18 Years | N/A | All | 160 | China | |
| 3 | JPRN-UMIN000015019 | 2014/09/02 | 02/09/2014 | Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG | Initial therapy for myasthenia gravis of combined therapy for tacrolimus and IVIG - Combined therapy for tacrolimus and IVIG | Myasthenia gravis | Tacrolimus and IVIG | Kansai medical university | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 20 | Not applicable | Japan |
| 4 | JPRN-UMIN000007679 | 2012/04/01 | 09/04/2012 | Randomized comparative study on efficacy and safety of tacrolimus, prednisolone or placebo in ocular myasthenia gravis patients | Randomized comparative study on efficacy and safety of tacrolimus, prednisolone or placebo in ocular myasthenia gravis patients - Efficacy and safety of tacrolimus in ocular myasthenia gravis | Myasthenia gravis | Administration of tacrolimus 3 mg/day Administration of prednisolone 5 mg/day anticholinesterases | Department of Neurology, Chiba University Graduate School of Medicine | NULL | Recruiting | 20years-old | Not applicable | Male and Female | 60 | Not selected | Japan |
| 5 | JPRN-UMIN000007671 | 2012/04/01 | 09/04/2012 | Randomized comparative study on efficacy and safety of reduced-dose steroid combined with tacrolimus vs conventional-dose steroid in late- or elderly-onset myasthenia gravis patients | Randomized comparative study on efficacy and safety of reduced-dose steroid combined with tacrolimus vs conventional-dose steroid in late- or elderly-onset myasthenia gravis patients - Steroid combined with tacrolimus for late- or elderly-onset patients of myasthenia gravis (STEP-MG) | Myasthenia gravis | Administration of prednisolone 35 mg/day with tacrolimus 3mg a day Administration of prednisolone 50 mg/day | Department of Neurology, Chiba University Graduate School of Medicine | NULL | Recruiting | 50years-old | Not applicable | Male and Female | 40 | Not applicable | Japan |
| 6 | NCT01325571 (ClinicalTrials.gov) | March 2011 | 16/3/2011 | A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis | A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy | Myasthenia Gravis | Drug: Tacrolimus capsule;Drug: Placebo | Astellas Pharma Inc | Astellas Pharma China, Inc. | Completed | 18 Years | 70 Years | Both | 83 | Phase 3 | China |
| 7 | NCT00309088 (ClinicalTrials.gov) | April 2006 | 29/3/2006 | FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients | FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients | Myasthenia Gravis | Drug: tacrolimus;Drug: placebo | Astellas Pharma Inc | NULL | Completed | 16 Years | 64 Years | Both | 80 | Phase 3 | Japan |
| 8 | NCT00309101 (ClinicalTrials.gov) | February 2006 | 29/3/2006 | An Open Study for Steroid Resistant, Non-Thymectomized MG Patients | FK506 Phase 3 Study: An Open Study for Steroid Resistant, Non-Thymectomized MG Patients | Myasthenia Gravis | Drug: tacrolimus | Astellas Pharma Inc | NULL | Completed | 16 Years | 64 Years | Both | 11 | Phase 3 | Japan |